263 related articles for article (PubMed ID: 20689132)
61. Proteomics of ovarian cancer: functional insights and clinical applications.
Elzek MA; Rodland KD
Cancer Metastasis Rev; 2015 Mar; 34(1):83-96. PubMed ID: 25736266
[TBL] [Abstract][Full Text] [Related]
62. Proteomics and translational medicine: molecular biomarkers for cancer diagnosis, prognosis and prediction of therapy outcome.
Cho WC
Expert Rev Proteomics; 2011 Feb; 8(1):1-4. PubMed ID: 21329422
[No Abstract] [Full Text] [Related]
63. Emerging diagnostic, prognostic and therapeutic biomarkers for ovarian cancer.
El Bairi K; Kandhro AH; Gouri A; Mahfoud W; Louanjli N; Saadani B; Afqir S; Amrani M
Cell Oncol (Dordr); 2017 Apr; 40(2):105-118. PubMed ID: 27981507
[TBL] [Abstract][Full Text] [Related]
64. [Early proteomics in ovarian cancer: myth or reality?].
Makarov OV; Govorun VM; Taranets IN; Goufman EI; Gritsaĭ AN; Archakov AI
Biomed Khim; 2003; 49(1):2-7. PubMed ID: 14569865
[TBL] [Abstract][Full Text] [Related]
65. Ovarian cancer proteomics: Many technologies one goal.
Narasimhan K; Changqing Z; Choolani M
Proteomics Clin Appl; 2008 Feb; 2(2):195-218. PubMed ID: 21136825
[TBL] [Abstract][Full Text] [Related]
66. Casting doubt on the traditional approach of cancer biomarker discovery through proteomics.
Kondo T
Expert Rev Proteomics; 2014 Feb; 11(1):9-12. PubMed ID: 24351084
[TBL] [Abstract][Full Text] [Related]
67. Proteomics beyond proteomics: toward clinical applications.
Plymoth A; Hainaut P
Curr Opin Oncol; 2011 Jan; 23(1):77-82. PubMed ID: 21107258
[TBL] [Abstract][Full Text] [Related]
68. Oncology biomarkers: discovery, validation, and clinical use.
Heckman-Stoddard BM
Semin Oncol Nurs; 2012 May; 28(2):93-8. PubMed ID: 22542316
[TBL] [Abstract][Full Text] [Related]
69. Quantitative Mass Spectrometry-Based Proteomics for Biomarker Development in Ovarian Cancer.
Ryu J; Thomas SN
Molecules; 2021 May; 26(9):. PubMed ID: 34063568
[TBL] [Abstract][Full Text] [Related]
70. Proteomics success story. Towards early detection of breast and ovarian cancer: plasma proteomics as a tool to find novel markers.
Souchelnytskyi S; Lomnytska M; Dubrovska A; Hellman U; Volodko N
Proteomics; 2006 Sep; 6 Suppl 2():65-8. PubMed ID: 17031801
[No Abstract] [Full Text] [Related]
71. New frontiers for ovarian cancer risk evaluation: proteomics and contrast-enhanced ultrasound.
Dutta S; Wang FQ; Fleischer AC; Fishman DA
AJR Am J Roentgenol; 2010 Feb; 194(2):349-54. PubMed ID: 20093595
[TBL] [Abstract][Full Text] [Related]
72. Ovarian Cancer Biomarkers: Moving Forward in Early Detection.
Bonifácio VDB
Adv Exp Med Biol; 2020; 1219():355-363. PubMed ID: 32130708
[TBL] [Abstract][Full Text] [Related]
73. Enzymes and related proteins as cancer biomarkers: a proteomic approach.
Liang SL; Chan DW
Clin Chim Acta; 2007 May; 381(1):93-7. PubMed ID: 17382922
[TBL] [Abstract][Full Text] [Related]
74. Markers of breast and gynecological malignancies: The clinical approach of proteomics-based studies.
Lomnytska M; Souchelnytskyi S
Proteomics Clin Appl; 2007 Sep; 1(9):1090-101. PubMed ID: 21136760
[TBL] [Abstract][Full Text] [Related]
75. Clinical application of proteomics in ovarian cancer prevention and treatment.
Meani F; Pecorelli S; Liotta L; Petricoin EF
Mol Diagn Ther; 2009; 13(5):297-311. PubMed ID: 19791834
[TBL] [Abstract][Full Text] [Related]
76. Proteomics in translational cancer research: biomarker discovery for clinical applications.
Cho WC
Expert Rev Proteomics; 2014 Apr; 11(2):131-3. PubMed ID: 24646121
[TBL] [Abstract][Full Text] [Related]
77. Mass spectrometry-based proteomics techniques and their application in ovarian cancer research.
Swiatly A; Plewa S; Matysiak J; Kokot ZJ
J Ovarian Res; 2018 Oct; 11(1):88. PubMed ID: 30270814
[TBL] [Abstract][Full Text] [Related]
78. In-depth quantitative proteomics for pancreatic cancer biomarker discovery.
Faca V; Hanash S
Expert Opin Med Diagn; 2007 Sep; 1(1):81-9. PubMed ID: 23489270
[TBL] [Abstract][Full Text] [Related]
79. Accelerating type-specific ovarian carcinoma research: Calculator for Ovarian Subtype Prediction (COSP) is a reliable high-throughput tool for case review.
Kommoss S; Gilks CB; Kommoss F; Chow C; Hilpert F; du Bois A; Köbel M; Huntsman DG; Anglesio M; Kalloger SE; Pfisterer J
Histopathology; 2013 Nov; 63(5):704-12. PubMed ID: 24033430
[TBL] [Abstract][Full Text] [Related]
80. Conventional and proteomic technologies for the detection of early stage malignancies: markers for ovarian cancer.
Lee CJ; Ariztia EV; Fishman DA
Crit Rev Clin Lab Sci; 2007; 44(1):87-114. PubMed ID: 17175521
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
